We are moving!

On December 18, 2021, Pure Biologics signed a contract for the lease of space for a new headquarters.

News

Inquiries

Pure Biologics has licensed the patented technology platform PureApta to Novaptech

30 November

2021

Pure Biologics has licensed the patented technology platform PureApta to Novaptech

Pure Biologics has licensed the patented technology platform PureApta™, comprising chemical modifications of aptamers and their applications, to French company Novaptech, who offers tests, sensors and other solutions based on aptamers.

“How Science Becomes Business” – Pure Biologics e-conference for investors

26 November

2021

“How Science Becomes Business” – Pure Biologics e-conference for investors

Find out more about the science behind our ideas and how we turn it into value.

Polski Związek Innowacyjnych Firm Biotechnologii Medycznej BioInMed (🇵🇱)

3 November

2021

Polski Związek Innowacyjnych Firm Biotechnologii Medycznej BioInMed (🇵🇱)

A new partner on the map of the innovation ecosystem (🇵🇱)

Pure Biologics at the Writing the Future of Drug Discovery and Development

8 October

2021

Pure Biologics at the Writing the Future of Drug Discovery and Development

Pure Biologics was invited to the event: "Writing the Future of Drug Discovery and Development", where it will present the first results of partnering with Twist Bioscience Corporation.

PB001 – completion of the first pilot preclinical study

30 August

2021

PB001 – completion of the first pilot preclinical study

Completion of the first preclinical pilot study in project PB001, in which Pure Biologics is developing a novel immunotherapy for the treatment of colorectal cancer.

9 October

2020

We are moving!

Pure Biologics has licensed the patented technology platform PureApta to Novaptech

“How Science Becomes Business” – Pure Biologics e-conference for investors

Polski Związek Innowacyjnych Firm Biotechnologii Medycznej BioInMed (🇵🇱)

Pure Biologics at the Writing the Future of Drug Discovery and Development

PB001 – completion of the first pilot preclinical study

Zapytanie Ofertowe – PB/MAGBBRIS/0/5/20 09.10.2020

Zapytanie Ofertowe – PB/MAGBBRIS/0/4/20 17.06.2020

Zapytanie Ofertowe – PB/MAGBBRIS/0/3/20 10.04.2020

Zapytanie Ofertowe – PB/MAGBBRIS/0/2/20 25.01.2020

Zapytanie Ofertowe – PB/MAGBBRIS/0/1/20 21.01.2020